Infectious disease
It was a very busy week for clinical trial updates. Here’s a look.
A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.
Novavax entered into an agreement to provide the United Kingdom with 60 million doses of the vaccine should it be approved, as well as a late-stage efficacy study in that country.
The results from a three-month study in more than 35,000 patients were published yesterday on a preprint server, which means they have not yet been peer-reviewed.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 14, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
While Russian President Vladimir Putin expressed confidence in the preventative medication against the novel coronavirus, scientists from across the globe expressed concern over the lack of available data.
Researchers at the University of California, Riverside leveraged machine learning to screen more than 10 million commercially available small molecules for interactions with SARS-CoV-2 viral proteins, and found hundreds of drugs that might offer treatments against COVID-19.
A recent report in the New England Journal of Medicine reveals that the racial and ethnic minority groups most negatively-impacted by COVID-19 are also the least represented in these clinical studies.
Although the world is eagerly awaiting news of an effective and safe vaccine against COVID-19, several companies are moving ahead testing therapeutic antibodies against the disease.
PRESS RELEASES